Clinical Trial Update: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update reports pharmacokinetic similarity between ABP-234, a pembrolizumab biosimilar, and Keytruda (pembrolizumab) in early-stage n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABP-234 (pembrolizumab biosimilar)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Amgen | Conditions: Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING